Manisha Vohra
Research Subjects
Manisha Vohra has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amit Sharma
Chitkara University
6 shared publications Ian Osoro
4 shared publicationsMohammad Amir
4 shared publications- Mohammad Amir
Department of Pharmacy Practice, ISF College of Pharmacy, Moga, GT Road, Ghal Kalan, Punjab, 142001, India
2 shared publications - Ranjeet Kumar
Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001, India
2 shared publications - Abrar Ahmad Zargar
Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India
1 shared publication
Latest Publications
- Open Access
- 1 September 2023
- Published by KEAI Publishing in Global Health Journal
- Vol. 7 (3) , 121-122
Revolutionizing patient care: the latest advancements in clinical pharmacy practice
- 1 September 2023
- Published by KEAI Publishing in Global Health Journal
- Vol. 7 (3) , 121-122
Open AccessRevolutionizing patient care: the latest advancements in clinical pharmacy practice
- Open Access
- 1 September 2023
- Published by KEAI Publishing in Global Health Journal
- Vol. 7 (3) , 123-129
Impact of vericiguat on heart failure with reduced ejection fraction: a review
- 1 September 2023
- Published by KEAI Publishing in Global Health Journal
- Vol. 7 (3) , 123-129
Open AccessImpact of vericiguat on heart failure with reduced ejection fraction: a review
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 4 (2) , 1
A Case Report on COVID-19 Causing New Onset of Diabetes Even with No History
This case report presents a case of a 51-year-old male patient who was found to be diabetic after recovering from COVID-19. Case Presentation: The patient was admitted to the COVID care center after testing positive for COVID-19 on November 2020. After spending one week in intensive care and ten days in the isolation ward of the COVID care center, he continued to feel multiple side effects. After fifteen days, he began showing signs of recovery and had no fever or other symptoms of COVID-19. The third SARS-Cov-2 RNA by RT-PCR sample test was also found to be negative. He was shifted to a non- COVID hospital when he became stable. For COVID-19, he was treated with supplementary oxygen therapy by keeping his oxygen level at 5L/min with titrating flow rate SpO2 of more than 90%. The hydroxychloroquine 400 mg orally BD for two days, followed by 200 mg orally BD for four days with a combination of azithromycin 500 mg orally OD for five days, was prescribed to him to treat COVID-19. Conclusion: According to the report "New-onset diabetes in COVID-19," published in the New England Journal of Medicine, there is a bidirectional relationship between COVID-19 and diabetes.
- 1 June 2023
- Published by Bentham Science Publishers Ltd. in Coronaviruses
- Vol. 4 (2) , 1
A Case Report on COVID-19 Causing New Onset of Diabetes Even with No History
This case report presents a case of a 51-year-old male patient who was found to be diabetic after recovering from COVID-19. Case Presentation: The patient was admitted to the COVID care center after testing positive for COVID-19 on November 2020. After spending one week in intensive care and ten days in the isolation ward of the COVID care center, he continued to feel multiple side effects. After fifteen days, he began showing signs of recovery and had no fever or other symptoms of COVID-19. The third SARS-Cov-2 RNA by RT-PCR sample test was also found to be negative. He was shifted to a non- COVID hospital when he became stable. For COVID-19, he was treated with supplementary oxygen therapy by keeping his oxygen level at 5L/min with titrating flow rate SpO2 of more than 90%. The hydroxychloroquine 400 mg orally BD for two days, followed by 200 mg orally BD for four days with a combination of azithromycin 500 mg orally OD for five days, was prescribed to him to treat COVID-19. Conclusion: According to the report "New-onset diabetes in COVID-19," published in the New England Journal of Medicine, there is a bidirectional relationship between COVID-19 and diabetes.
- Open Access
- 21 March 2023
- Published by Elsevier in Health Sciences Review
- Vol. 7
Adaptogenic herbs: A natural way to improve athletic performance
- 21 March 2023
- Published by Elsevier in Health Sciences Review
- Vol. 7
Open AccessAdaptogenic herbs: A natural way to improve athletic performance
- Open Access
A Scoping Review on COVID-19-Induced Cardiovascular Complications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a type of human coronavirus that resulted in the 2019 coronavirus disease (COVID-19). Although it was generally categorized as a respiratory disease, its involvement in cardiovascular complications was identified from the onset. Elevated cardiac troponin levels (a myocardial injury marker) and echocardiograms, which showed the anomalous performance of the patients’ hearts, were noted in the early case reports obtained from Wuhan, China. A couple of mechanisms have been proposed to explain COVID-19-induced cardiovascular complications, with systemic inflammation being the major focus recently. Chest pain and palpitations are among the prevalent symptoms in moderate to severe COVID-19-recovering patients. Cardiac damage potentially occurs due to multifactorial factors, which include cytokine-induced inflammation, direct cardiotoxicity, and disseminated intravascular coagulation (DIC), among others. The cardiovascular manifestations include cardiac arrhythmia, cardiogenic shock, venous thromboembolism, and elevated cardiac biomarkers. Both the long- and short-term effects of these cardiovascular complications remain puzzling to researchers, as substantial evidence is yet to be gathered to reach a consensus on the severity of COVID-19 in the heart. The treatment considerations currently include antiarrhythmic management, ACEI or ARB use, anticoagulation, hemodynamic support, and immunosuppression. This review aimed to outline the pathogenesis of the various cardiac complications due to COVID-19 as well as the available treatment modalities of COVID-19 infection. Both the mechanisms and the treatments have been succinctly explained in a proper manner to ensure understanding.
Open AccessA Scoping Review on COVID-19-Induced Cardiovascular Complications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a type of human coronavirus that resulted in the 2019 coronavirus disease (COVID-19). Although it was generally categorized as a respiratory disease, its involvement in cardiovascular complications was identified from the onset. Elevated cardiac troponin levels (a myocardial injury marker) and echocardiograms, which showed the anomalous performance of the patients’ hearts, were noted in the early case reports obtained from Wuhan, China. A couple of mechanisms have been proposed to explain COVID-19-induced cardiovascular complications, with systemic inflammation being the major focus recently. Chest pain and palpitations are among the prevalent symptoms in moderate to severe COVID-19-recovering patients. Cardiac damage potentially occurs due to multifactorial factors, which include cytokine-induced inflammation, direct cardiotoxicity, and disseminated intravascular coagulation (DIC), among others. The cardiovascular manifestations include cardiac arrhythmia, cardiogenic shock, venous thromboembolism, and elevated cardiac biomarkers. Both the long- and short-term effects of these cardiovascular complications remain puzzling to researchers, as substantial evidence is yet to be gathered to reach a consensus on the severity of COVID-19 in the heart. The treatment considerations currently include antiarrhythmic management, ACEI or ARB use, anticoagulation, hemodynamic support, and immunosuppression. This review aimed to outline the pathogenesis of the various cardiac complications due to COVID-19 as well as the available treatment modalities of COVID-19 infection. Both the mechanisms and the treatments have been succinctly explained in a proper manner to ensure understanding.
- Open Access
- 5 January 2023
- Published by Elsevier in Health Sciences Review
- Vol. 6
Formulation strategies for nose-to-brain drug delivery in Alzheimer's disease
- 5 January 2023
- Published by Elsevier in Health Sciences Review
- Vol. 6
Open AccessFormulation strategies for nose-to-brain drug delivery in Alzheimer's disease
- Open Access
- 17 November 2022
- Published by Elsevier in Health Sciences Review
- Vol. 5
Prevention and management of anthracycline induced cardiotoxicity: A review
- 17 November 2022
- Published by Elsevier in Health Sciences Review
- Vol. 5
Open AccessPrevention and management of anthracycline induced cardiotoxicity: A review